-
Lee’s Pharmaceutical Wins NMPA Approval for ALS Drug Teglutik
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has announced receiving market approval from the National Medical Products Administration (NMPA) for its drug Teglutik (riluzole), intended to prolong the life of patients with amyotrophic lateral sclerosis (ALS) or delay the need for mechanical ventilation. Drug Background and MechanismTeglutik, a neuroprotective agent…
-
Winsan Medical Acquires 52% Stake in Goodfeel Dental Clinic for RMB 156 Million
•
China-based Winsan (Chengdu) Medical Science and Technology Co., Ltd (SHA: 600767) is set to acquire a 52% stake in compatriot firm Goodfeel Dental Clinic for a consideration of RMB 156 million (USD 23.2 million). Financial Details and Profit AssuranceThe acquisition values Goodfeel Dental Clinic at approximately RMB 300 million (USD…
-
InnoCare Pharma’s ICP-189 First Dosed in China SHP2 Inhibitor Trial
•
Beijing InnoCare Pharma (HKG: 9969) has announced the first patient dosing in a clinical study of its protein tyrosine phosphatase (SHP2) allosteric inhibitor ICP-189 in China. The drug is being developed to treat liver cancer, head and neck cancer, digestive tract tumors, and other solid tumors. Mechanism and Preclinical ResultsICP-189…
-
China NT Pharma Group Inks Licensing Deal for Orticumab in Asia
•
China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a licensing agreement with US firm Abcentra LLC. Under the terms, its subsidiary Green-Life Technology (Hong Kong) Co., Ltd will gain exclusive, permanent commercial rights to NT Pharma’s monoclonal antibody orticumab for Greater China, Singapore, Malaysia, and Thailand. Orticumab,…
-
Mega Genomics Limited Makes Hong Kong IPO Debut at HKD 18 Per Share
•
China-based gene testing platform company Mega Genomics Limited has successfully completed an initial public offering (IPO) of 12 million shares on the Hong Kong Stock Exchange at HKD 18 (USD 2.98) per share. The offering, sponsored by China Securities, marks a significant milestone for the company as it seeks to…
-
Venus Medtech’s VenusP-Valve Used Compassionately in US for Pulmonary Regurgitation
•
Venus Medtech (Hangzhou) Inc. (HKG: 2500) announced the first compassionate use of its VenusP-Valve, a transcatheter pulmonary valve replacement (TPVR) system, at the University of Virginia Advanced Cardiac Valve Center in the United States. This procedure marks a significant milestone for the VenusP-Valve, which is designed to treat patients with…
-
Merck KGaA’s Erbitux Approved in China for Head and Neck Cancer Treatment
•
Germany-based pharmaceutical firm Merck KGaA announced that China’s National Medical Products Administration (NMPA) has issued market approval for a new indication for the epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab). The approval allows Erbitux to be used in combination with radiotherapy for treating locally advanced squamous cell carcinoma of…
-
CSPC’s JMT103 Accepted for Review in China, Targets RANKL-Related Deficiencies
•
The Center for Drug Evaluation (CDE) website indicates that a market filing by China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) subsidiary Shanghai JMT Biotechnology Co., Ltd for its anti-RANKL monoclonal antibody (mAb) JMT103 has been accepted for review. This next-generation RANKL antibody aims to address the shortcomings of existing marketed…
-
Grand Pharma Launches SIR-Spheres for Liver Cancer Treatment in China
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the official launch of its SIR-Spheres (Y-90 microsphere injection) in mainland China for the treatment of malignant liver tumors. The product received approval in February 2022 for patients with unresectable liver metastases from colorectal cancer who have failed standard therapy. Product…
-
Beijing Introduces White List System for Biomedical R&D Item Imports
•
Beijing has announced the introduction of a ‘white list’ system to facilitate the import of items essential for drug research and development (R&D) by companies operating within the city. This initiative is outlined in the “Beijing Biomedical Research and Development Items Import Pilot Plan,” jointly released by multiple municipal authorities,…
-
Ocumension Therapeutics’ OT-401 Approved for Chronic Non-Infectious Uveitis in China
•
China-based Ocumension Therapeutics (HKG: 1477) has received approval from the National Medical Products Administration (NMPA) for its drug OT-401 (fluocinolone intravitreal implant) for treating chronic non-infectious uveitis. This marks a significant milestone as the first new drug approved in China based on real-world data (RWD), accelerating its commercialization by approximately…
-
AstraZeneca Expands in China with Qingdao Partnership and Manufacturing Base
•
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is significantly expanding its presence in China through a strategic partnership with the municipal government of Qingdao, Shandong province. The collaboration encompasses the establishment of a manufacturing and supply base, regional headquarters, a rare disease innovation center, a life science innovation park, and an…
-
CStone Pharmaceuticals’ Ayvakit Included in Taiwan’s National Health Insurance
•
China-based CStone Pharmaceuticals (HKG: 2616) announced that its Ayvakit (avapritinib), a tyrosine kinase inhibitor for treating gastrointestinal stromal tumors (GIST), has been included in Taiwan’s National Health Insurance, effective June 1, 2022. Drug Approval and BackgroundAvapritinib received approval in Taiwan under the trade name TaiShiWei in 2021 for adult patients…
-
Eureka Biotechnology Secures RMB 100 Million for Cell and Gene Therapy Solutions
•
Shenzhen-based Eureka Biotechnology, a company specializing in comprehensive solutions for the cell and gene therapy industry, has reportedly secured RMB 100 million (USD 14.97 million) in a Series B financing round. The funding, led by Eight Roads Capital and joined by Shenzhen Jiufite Private Equity Investment Management and Juke Investment,…
-
Therorna Secures Over RMB 280 Million in Series A Round to Accelerate circRNA Tech Development
•
China-based Therorna Inc., a biotech company specializing in cutting-edge circular RNA (circRNA) technology for next-generation vaccines and therapies, has completed a Series A financing round exceeding RMB 280 million (USD 41.8 million). The round was led by a well-known industrial investment firm and MSA Capital, with participation from Sherpa Healthcare…
-
Qingdao HuaRen Pharmaceutical Gains CE Marks for Monkeypox and COVID-19 Detection Kits
•
China-based Qingdao HuaRen Pharmaceutical Co., Ltd (SHE: 300110) has announced receiving CE marks in the European Union (EU) for its monkeypox virus nucleic acid detection kit (fluorescent PCR method) and novel coronavirus (SARS-CoV-2) antigen detection kit. Monkeypox Virus Detection KitThe monkeypox virus nucleic acid detection kit uses a real-time fluorescent…
-
SSY Group’s Blonanserin and Paracetamol Approved by China’s NMPA
•
China-based SSY Group Limited (HKG: 2005) has announced receiving market approvals from the National Medical Products Administration (NMPA) for its generic versions of blonanserin, paracetamol, mannitol, and levofloxacin. Notably, the generic versions of blonanserin and paracetamol are the first of their kind to be approved in China. Drug Details and…
-
Shanghai ShineYo Medical Device Secures RMB 100 Million in Series A Round
•
Shanghai ShineYo Medical Device Co., Ltd, a company specializing in electrophysiology and peripheral intervention, has reportedly secured RMB 100 million (USD 14.93 million) in a Series A financing round. The funding was led by Apricot Capital and Industrial Securities Capital, with participation from Dalton Venture, Bangming Capital, and HiMed Angle…
-
Boehringer Ingelheim Venture Fund and Hong Kong Science Park Launch Co-Incubation Plan
•
Germany-based pharmaceutical giant Boehringer Ingelheim’s venture fund (BIVF) and China-based Hong Kong Science & Technology Parks Corporation have announced a co-incubation plan aimed at promoting and incubating startups in the fields of infectious diseases and immunology. Collaboration ObjectivesThe initiative seeks to accelerate the translation of cutting-edge science into innovative treatments,…
-
Innovent Biologics’ Tyvyt Approved for First-Line Esophageal Squamous Cell Carcinoma
•
The National Medical Products Administration (NMPA) website indicates that China-based Innovent Biologics, Inc. (HKG: 1801) has received approval for a new indication of its PD-1 inhibitor Tyvyt (sintilimab) for the treatment of first-line esophageal squamous cell carcinoma (ESCC). This marks the fifth indication approval for the drug in China. Drug…
